This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. AMPE, SCPS, CALA, EVLO, CMRA, ARDS, HSTO, STAB, CLVR, and EFTRShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Ampio Pharmaceuticals (AMPE), Scopus BioPharma (SCPS), Calithera Biosciences (CALA), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Histogen (HSTO), Statera Biopharma (STAB), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Its Competitors Ampio Pharmaceuticals Scopus BioPharma Calithera Biosciences Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Histogen Statera Biopharma Clever Leaves eFFECTOR Therapeutics Ampio Pharmaceuticals (NYSE:AMPE) and Conatus Pharmaceuticals (NASDAQ:CNAT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do institutionals and insiders believe in AMPE or CNAT? 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 15.2% of Conatus Pharmaceuticals shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 11.3% of Conatus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor AMPE or CNAT? Conatus Pharmaceuticals received 537 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmpio PharmaceuticalsOutperform VotesNo VotesUnderperform Votes78100.00% Conatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Which has higher valuation and earnings, AMPE or CNAT? Ampio Pharmaceuticals has higher earnings, but lower revenue than Conatus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00Conatus Pharmaceuticals$21.72M0.00-$11.39MN/AN/A Which has more volatility & risk, AMPE or CNAT? Ampio Pharmaceuticals has a beta of 4.92, suggesting that its share price is 392% more volatile than the S&P 500. Comparatively, Conatus Pharmaceuticals has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Is AMPE or CNAT more profitable? Ampio Pharmaceuticals has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Ampio Pharmaceuticals' return on equity of 0.00% beat Conatus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A Conatus Pharmaceuticals -52.42%-48.22%-39.32% Does the media refer more to AMPE or CNAT? In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Conatus Pharmaceuticals'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral Conatus Pharmaceuticals Neutral SummaryAmpio Pharmaceuticals beats Conatus Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$36K$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio0.008.7827.1320.06Price / Sales0.00255.64412.28157.10Price / CashN/A65.8538.2534.64Price / Book0.006.557.064.70Net Income-$11.39M$143.93M$3.23B$247.88M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.00flatN/A-99.6%$36K$21.72M0.0030AMPEAmpio Pharmaceuticals0.2964 of 5 stars$0.13flatN/A-97.9%$148KN/A-0.0120SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009High Trading VolumeCALACalithera Biosciences0.6238 of 5 stars$0.00flatN/A-90.0%$10KN/A0.0060Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00-66.7%N/A-99.8%$5K$3.09M0.0030Gap DownHSTOHistogenN/A$0.00flatN/A-99.4%$5K$19K0.0020STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020CLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00+100.0%N/A-100.0%$1K$3.55M0.0010Gap Up Related Companies and Tools Related Companies Ampio Pharmaceuticals Competitors Scopus BioPharma Competitors Calithera Biosciences Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Aridis Pharmaceuticals Competitors Histogen Competitors Statera Biopharma Competitors Clever Leaves Competitors eFFECTOR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
